Researchers in the laboratory of Zhiqiang An, Ph.D., are working on innovative treatments for cancer and other human diseases. In particular, they are developing targeted treatments involving the use of proteins called antibodies that can be engineered to latch onto tumor cells and disrupt their growth. These drugs are associated with fewer side effects. An’s research is supported by the Cancer Prevention & Research Institute of Texas, the National Institutes of Health and the pharmacy industry. Prior to joining the faculty of the UTHealth Medical School, An served as an executive in the biotechnology and pharmaceutical industry.